Welcome to our dedicated page for Ufp Technologies SEC filings (Ticker: UFPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding patent roll-forwards or segment margins hidden inside UFP Technologies’ dense disclosures can feel like navigating a maze. Whether you need to verify UFP Technologies insider trading Form 4 transactions or trace how new clean-room capacity affects gross profit, the company’s multi-industry footprint makes every report a technical deep dive. UFP Technologies SEC filings explained simply is what most analysts want—yet few have the time to sift through hundreds of pages.
Stock Titan removes that hurdle. Our AI turns each UFP Technologies annual report 10-K simplified and every UFP Technologies quarterly earnings report 10-Q filing into concise plain-English summaries. Need alerts on UFP Technologies Form 4 insider transactions real-time or a quick take on a sudden capacity expansion disclosed in an 8-K? You’ll receive UFP Technologies 8-K material events explained in minutes. The platform also links directly to the proxy so you can review UFP Technologies proxy statement executive compensation without fishing through EDGAR. For traders who monitor management activity, we surface UFP Technologies executive stock transactions Form 4 alongside context-rich charts. It’s all part of understanding UFP Technologies SEC documents with AI.
Professionals use these insights to:
- Conduct fast UFP Technologies earnings report filing analysis and spot quarter-over-quarter swings in medical versus industrial revenue.
- Track insider sentiment before product launches or facility upgrades.
- Compare cap-ex plans to patent additions, gauging how innovation drives growth.
With real-time updates, AI-powered summaries and full coverage of every filing type, Stock Titan lets you move from raw disclosure to actionable clarity in seconds.
Form 144 notice for UFP Technologies Inc. (UFPT) shows a proposed sale of 2,873 shares of common stock through UBS Financial Services with an aggregate market value of $591,883. The shares represent part of the company's listed outstanding shares of 7,711,126 and the proposed approximate sale date is 09/05/2025 on NASDAQ.
The filing discloses the acquisition history for the shares to be sold: 1,318 shares were acquired by exercising options on 08/07/2025 (paid in cash), and the remainder came from vesting of stock unit awards on 05/31/2022 (610 shares), 05/31/2023 (647 shares), and 05/31/2024 (298 shares) with the awards treated as compensation. The filer reports no sales of issuer securities in the past three months.
Daniel C. Croteau, a director of UFP Technologies, acquired 1,318 shares of common stock on 08/07/2025 at a reported price of $22.36 per share, increasing his direct beneficial ownership to 3,728 shares. The transaction corresponds to the exercise of a stock option with a $22.36 exercise price originally exercisable on 12/16/2015 and expiring on 12/16/2025. The Form 4 was signed by an attorney-in-fact on 08/14/2025.
UFP Technologies reported significant revenue and profit growth driven largely by recent acquisitions while facing margin pressure, higher interest expense, and customer concentration.
Net sales were $151.2 million for the quarter (up 37.2% year-over-year) and $299.3 million for the six months (up 39.1%). Net income was $17.2 million in the quarter and $34.4 million year-to-date, with diluted EPS of $2.21 for the quarter and $4.42 for six months. Gross margin declined to 28.8% in Q2 from 30.0% due to higher material, labor and onboarding inefficiencies at newly acquired AJR operations. SG&A rose in absolute dollars but decreased as a percentage of sales to 12.4% in Q2.
The company completed multiple acquisitions that expanded its medical-market capabilities and geography, including AJR Enterprises ($110.7M), AQF ($47.7M), Welch ($35.2M), Marble ($5.0M) and AJR Specialty ($2.8M); these collectively contributed about $76.3M in sales in H1 2025. Long-term debt outstanding was $163.6 million with Q2 interest expense of $2.7 million; cash from operations was $39.1 million for six months. Management disclosed contingent consideration obligations, tariff exposure estimated at ~$9 million annually, and customer concentration with two customers representing ~27.4% and ~20.3% of Q2 sales.
FAQ
What is the current stock price of Ufp Technologies (UFPT)?
What is the market cap of Ufp Technologies (UFPT)?
